NMRA
Price:
$1.51
Market Cap:
$279.78M
Neumora Therapeutics, Inc. is a specialized biopharmaceutical company progressing through clinical trials, dedicated to advancing therapies for a range of neurological, psychiatric, and neurodegenerative conditions. Its most advanced candidate, navacaprant (also known as NMRA-140), is a novel, once-daily oral kappa opioid receptor antagonist currently undergoing Phase 3 clinical trials for the management of major depressive disorder. Additionally, NMRA-511 is in Phase 1 studies, targeting agitation experienced by individuals with Alzheimer's-related dementia. Another compound, NMRA-266, is also in Phase 1 clinical development, aimed at addressing schizophrenia and other related neuropsychiat...[Read more]
Industry
Biotechnology
IPO Date
2023-09-15
Stock Exchange
NASDAQ
Ticker
NMRA
According to Neumora Therapeutics, Inc. Common Stock’s latest financial reports and current stock price. The company's current ROE is -181.70%. This represents a change of 255.15% compared to the average of -51.16% of the last 4 quarters.
The mean historical ROE of Neumora Therapeutics, Inc. Common Stock over the last ten years is -22.27%. The current -181.70% ROE has changed 715.96% with respect to the historical average. Over the past ten years (40 quarters), NMRA's ROE was at its highest in in the September 2021 quarter at 59.25%. The ROE was at its lowest in in the March 2026 quarter at -75.63%.
Average
-22.27%
Median
0%
Minimum
-228.10%
Maximum
105.18%
Discovering the peaks and valleys of Neumora Therapeutics, Inc. Common Stock ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = Infinity%
Maximum Annual ROE = 105.18%
Minimum Annual Increase = -271.69%
Minimum Annual ROE = -228.10%
| Year | ROE | Change |
|---|---|---|
| 2025 | -228.10% | 168.59% |
| 2024 | -84.92% | 68.85% |
| 2023 | -50.30% | -271.69% |
| 2022 | 29.29% | -59.85% |
| 2021 | 72.97% | -30.62% |
| 2020 | 105.18% | Infinity% |
The current ROE of Neumora Therapeutics, Inc. Common Stock (NMRA) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-121.11%
5-year avg
-52.21%
10-year avg
-22.27%
Neumora Therapeutics, Inc. Common Stock’s ROE is greater than RAPT Therapeutics, Inc. (-61.81%), greater than Bicycle Therapeutics plc (-35.74%), greater than Omeros Corporation (-54.39%), less than ADC Therapeutics S.A. (65.27%), greater than Lexicon Pharmaceuticals, Inc. (-18.64%), greater than Alumis Inc. Common Stock (-54.63%), greater than Fulcrum Therapeutics, Inc. (-27.80%), greater than 4D Molecular Therapeutics, Inc. (-36.83%), greater than Prothena Corporation plc (-49.88%), greater than Autolus Therapeutics plc (-128.53%),
| Company | ROE | Market cap |
|---|---|---|
| -61.81% | $959.26M | |
| -35.74% | $277.58M | |
| -54.39% | $744.02M | |
| 65.27% | $138.64M | |
| -18.64% | $892.83M | |
| -54.63% | $2.89B | |
| -27.80% | $200.21M | |
| -36.83% | $504.99M | |
| -49.88% | $467.51M | |
| -128.53% | $401.88M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Neumora Therapeutics, Inc. Common Stock using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Neumora Therapeutics, Inc. Common Stock or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the ROE?
How can you use the ROE?
What is Neumora Therapeutics, Inc. Common Stock's ROE?
How is the ROE calculated for Neumora Therapeutics, Inc. Common Stock (NMRA)?
What is the highest ROE for Neumora Therapeutics, Inc. Common Stock (NMRA)?
What is the 3-year average ROE for Neumora Therapeutics, Inc. Common Stock (NMRA)?
What is the 5-year average ROE for Neumora Therapeutics, Inc. Common Stock (NMRA)?
How does the current ROE for Neumora Therapeutics, Inc. Common Stock (NMRA) compare to its historical average?